A small study finds that an off-the-shelf vaccine candidate by Elicio Therapeutics boosted immune response in pancreatic ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

Federal funding cuts to mRNA technology research doesn't just impact COVID vaccines — experts say it could stall progress in treatment for cancers, rare disease and more.

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal ...

A new 'off-the-shelf' vaccine with the catchy name ELI-002 2P offers fresh hope for individuals affected by these deadly ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back ...

A one-size-fits-all vaccine has shown promising results in keeping hard-to-treat pancreatic cancers from coming back. The ...

Cancer rates in 2025 are predicted to exceed the previous year's statistics, with one-in-three men and women both at risk of contracting the disease.

Black and Hispanic people are more likely to be diagnosed with pancreatic cancer and more likely to die from it. Now, one drug may help fix this.